Inventor
JR., David R. LANCIA
Inventor
US
Overview
Patents· 25 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
C07DHeterocyclic compounds31%
A61KPreparations for medical, dental or toiletry purposes26%
Y02ATechnologies for adaptation to climate change9%
C07CAcyclic or carbocyclic compounds4%
PatentTitleYear
12,479,807Methods using HDAC11 inhibitors202512,304,904Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors202512,275,715Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors202512,264,1373-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors202512,128,035Activating pyruvate kinase R202412,122,778Activating pyruvate kinase R202412,071,440Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators202412,053,458Treating sickle cell disease with a pyruvate kinase R activating compound202412,018,030Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors202411,980,611Treating sickle cell disease with a pyruvate kinase R activating compound202411,919,839Alpha-cinnamide compounds and compositions as HDAC8 inhibitors202411,891,3653-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors202411,844,787Activating pyruvate kinase R202311,739,071Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors202311,702,412Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors202311,649,242Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators202311,535,607Isoindolines as HDAC inhibitors202211,498,913Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors202211,414,392[6,6] fused bicyclic HDAC8 inhibitors202211,396,513Compositions for activating pyruvate kinase202211,345,672Methods using HDAC11 inhibitors202211,325,917Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors202211,279,6813-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors202211,274,0843-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors202211,274,0853-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2025Patents assigned to VALO HEALTH INC (15)· patent assignee history
2022–2025Patents assigned to FORMA THERAPEUTICS INC (4)· patent assignee history
2022–2025Based in US· patent location history
2023–2024Patents assigned to NOVO NORDISK HEALTHCARE AG (6)· patent assignee history
2023Patents assigned to VALO EARLY DISCOVERY INC (1)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| VALO HEALTH INC | 15 | 2022–2025 |
| NOVO NORDISK HEALTHCARE AG | 6 | 2023–2024 |
| FORMA THERAPEUTICS INC | 4 | 2022–2025 |
| VALO EARLY DISCOVERY INC | 1 | 2023 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 25 | 2022–2025 |